Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals

Lars Peters; Kamilla Laut; Chiara Resnati; Santos Del Campo; Clifford Leen; Karolin Falconer; Tatyana Trofimova; Dzmitry Paduta; Jose Gatell; Andri Rauch; Karine Lacombe; Pere Domingo; Nikoloz Chkhartishvili; Robert Zangerle; Raimonda Matulionyte; Viktar Mitsura; Thomas Benfield; Kai Zilmer; Irina Khromova; Jens Lundgren; Jürgen Rockstroh; Amanda Mocroft; Eurosida Study Group

doi:10.1097/QAD.0000000000001928

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals

Lars Peters^*, Kamilla Laut, Chiara Resnati, Santos Del Campo, Clifford Leen, Karolin Falconer, Tatyana Trofimova, Dzmitry Paduta, Jose Gatell, Andri Rauch, Karine Lacombe, Pere Domingo, Nikoloz Chkhartishvili, Robert Zangerle, Raimonda Matulionyte, Viktar Mitsura, Thomas Benfield, Kai Zilmer, Irina Khromova, Jens LundgrenJürgen Rockstroh, Amanda Mocroft, Eurosida Study Group

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin

9 Citationer (Scopus)

Abstract

Background and aims: To investigate the uptake of hepatitisCvirus (HCV) therapy among HIV/HCV-coinfectedpatients inthepan-EuropeanEuroSIDAstudybetween2011and2016. Methods: All HCV-RNA patients were included. Baseline was defined as latest of anti-HCV , January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-Acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression. Results: Among 4308HCV-RNA patients (1255, 970, 663, 633, 787 fromSouth,West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113(25.8%)started anyHCVtherapy.Among patients with at least F3 fibrosis,more than 50% in all regions remained untreated. The incidence (per 1000 person-years of followup, 95% confidence interval) of starting DAA increased from 7.8 (5.9 9.8) in 2014 to 135.2 (122.0 148.5) in 2015 and 128.9 (113.5 144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals fromCentral East or East, genotype 3, antiretroviral therapy nai ve and those with detectable HIV-RNAwere less likely to start DAA. Older persons, those withHCV-RNAmore than 500 000 IU/ml and those withmore advanced liver fibrosis were more likely to start DAA. Conclusion: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.

Originalsprog	Engelsk
Tidsskrift	AIDS (London, England)
Vol/bind	32
Udgave nummer	14
Sider (fra-til)	1995-2004
Antal sider	10
ISSN	0269-9370
DOI	https://doi.org/10.1097/QAD.0000000000001928
Status	Udgivet - 10 sep. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1097/QAD.0000000000001928

Citationsformater

Peters, L., Laut, K., Resnati, C., Del Campo, S., Leen, C., Falconer, K., Trofimova, T., Paduta, D., Gatell, J., Rauch, A., Lacombe, K., Domingo, P., Chkhartishvili, N., Zangerle, R., Matulionyte, R., Mitsura, V., Benfield, T., Zilmer, K., Khromova, I., ... Eurosida Study Group (2018). Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS (London, England), 32(14), 1995-2004. https://doi.org/10.1097/QAD.0000000000001928

Peters, L, Laut, K, Resnati, C, Del Campo, S, Leen, C, Falconer, K, Trofimova, T, Paduta, D, Gatell, J, Rauch, A, Lacombe, K, Domingo, P, Chkhartishvili, N, Zangerle, R, Matulionyte, R, Mitsura, V, Benfield, T, Zilmer, K, Khromova, I, Lundgren, J, Rockstroh, J, Mocroft, A & Eurosida Study Group 2018, 'Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals', AIDS (London, England), bind 32, nr. 14, s. 1995-2004. https://doi.org/10.1097/QAD.0000000000001928

@article{b09fdf682e624be0a595ead87729ccac,

title = "Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals",

abstract = "Background and aims: To investigate the uptake of hepatitisCvirus (HCV) therapy among HIV/HCV-coinfectedpatients inthepan-EuropeanEuroSIDAstudybetween2011and2016. Methods: All HCV-RNA patients were included. Baseline was defined as latest of anti-HCV , January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-Acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression. Results: Among 4308HCV-RNA patients (1255, 970, 663, 633, 787 fromSouth,West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113(25.8%)started anyHCVtherapy.Among patients with at least F3 fibrosis,more than 50% in all regions remained untreated. The incidence (per 1000 person-years of followup, 95% confidence interval) of starting DAA increased from 7.8 (5.9 9.8) in 2014 to 135.2 (122.0 148.5) in 2015 and 128.9 (113.5 144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals fromCentral East or East, genotype 3, antiretroviral therapy nai ve and those with detectable HIV-RNAwere less likely to start DAA. Older persons, those withHCV-RNAmore than 500 000 IU/ml and those withmore advanced liver fibrosis were more likely to start DAA. Conclusion: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.",

author = "Lars Peters and Kamilla Laut and Chiara Resnati and {Del Campo}, Santos and Clifford Leen and Karolin Falconer and Tatyana Trofimova and Dzmitry Paduta and Jose Gatell and Andri Rauch and Karine Lacombe and Pere Domingo and Nikoloz Chkhartishvili and Robert Zangerle and Raimonda Matulionyte and Viktar Mitsura and Thomas Benfield and Kai Zilmer and Irina Khromova and Jens Lundgren and J{\"u}rgen Rockstroh and Amanda Mocroft and {Eurosida Study Group}",

year = "2018",

month = sep,

day = "10",

doi = "10.1097/QAD.0000000000001928",

language = "English",

volume = "32",

pages = "1995--2004",

journal = "AIDS (London, England)",

issn = "0269-9370",

publisher = "Lippincott Williams & Wilkins",

number = "14",

}

TY - JOUR

T1 - Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals

AU - Peters, Lars

AU - Laut, Kamilla

AU - Resnati, Chiara

AU - Del Campo, Santos

AU - Leen, Clifford

AU - Falconer, Karolin

AU - Trofimova, Tatyana

AU - Paduta, Dzmitry

AU - Gatell, Jose

AU - Rauch, Andri

AU - Lacombe, Karine

AU - Domingo, Pere

AU - Chkhartishvili, Nikoloz

AU - Zangerle, Robert

AU - Matulionyte, Raimonda

AU - Mitsura, Viktar

AU - Benfield, Thomas

AU - Zilmer, Kai

AU - Khromova, Irina

AU - Lundgren, Jens

AU - Rockstroh, Jürgen

AU - Mocroft, Amanda

AU - Eurosida Study Group

PY - 2018/9/10

Y1 - 2018/9/10

N2 - Background and aims: To investigate the uptake of hepatitisCvirus (HCV) therapy among HIV/HCV-coinfectedpatients inthepan-EuropeanEuroSIDAstudybetween2011and2016. Methods: All HCV-RNA patients were included. Baseline was defined as latest of anti-HCV , January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-Acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression. Results: Among 4308HCV-RNA patients (1255, 970, 663, 633, 787 fromSouth,West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113(25.8%)started anyHCVtherapy.Among patients with at least F3 fibrosis,more than 50% in all regions remained untreated. The incidence (per 1000 person-years of followup, 95% confidence interval) of starting DAA increased from 7.8 (5.9 9.8) in 2014 to 135.2 (122.0 148.5) in 2015 and 128.9 (113.5 144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals fromCentral East or East, genotype 3, antiretroviral therapy nai ve and those with detectable HIV-RNAwere less likely to start DAA. Older persons, those withHCV-RNAmore than 500 000 IU/ml and those withmore advanced liver fibrosis were more likely to start DAA. Conclusion: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.

AB - Background and aims: To investigate the uptake of hepatitisCvirus (HCV) therapy among HIV/HCV-coinfectedpatients inthepan-EuropeanEuroSIDAstudybetween2011and2016. Methods: All HCV-RNA patients were included. Baseline was defined as latest of anti-HCV , January 2011 or enrolment in EuroSIDA. The incidence of starting first interferon-free direct-Acting antiviral (DAA) therapy was calculated. Factors associated with starting interferon-free DAA were determined by Poisson regression. Results: Among 4308HCV-RNA patients (1255, 970, 663, 633, 787 fromSouth,West, North, Central East and East Europe, respectively) with 11 863 person-years of follow-up, 1113(25.8%)started anyHCVtherapy.Among patients with at least F3 fibrosis,more than 50% in all regions remained untreated. The incidence (per 1000 person-years of followup, 95% confidence interval) of starting DAA increased from 7.8 (5.9 9.8) in 2014 to 135.2 (122.0 148.5) in 2015 and 128.9 (113.5 144.3) in 2016. The increase was highest in North and West and intermediate in South, but remained modest in Central East and Eastern Europe. After adjustment, women, individuals fromCentral East or East, genotype 3, antiretroviral therapy nai ve and those with detectable HIV-RNAwere less likely to start DAA. Older persons, those withHCV-RNAmore than 500 000 IU/ml and those withmore advanced liver fibrosis were more likely to start DAA. Conclusion: Uptake of DAA therapy among HIV/HCV-coinfected patients increased considerably in Western Europe between 2014 and 2016, but was modest in Central East and East. In all regions more than 50% with at least F3 fibrosis remained untreated. Women were less likely to start DAA.

U2 - 10.1097/QAD.0000000000001928

DO - 10.1097/QAD.0000000000001928

M3 - Journal article

C2 - 29912062

SN - 0269-9370

VL - 32

SP - 1995

EP - 2004

JO - AIDS (London, England)

JF - AIDS (London, England)

IS - 14

ER -

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater